SEER

Seer, Inc.

Healthcare · $107M market cap

Verdict

We can't put a fair value on SEER right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-14.1% a year✗
Sales growth9.3% a year✗
Free cash flow growth—?
Return on invested capital-26.8%✗

Follow SEER

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Nov 2, 2026: no open-market purchases and 2 other filings (stock awards, tax withholding and similar). Why purchases matter

Other filings

Questions about SEER

Are insiders buying SEER?

Since Nov 2, 2026: no open-market purchases and 2 other filings (stock awards, tax withholding and similar).

How can I check SEER's value myself?

Use the free Sticker Price calculator, already filled with SEER's numbers. Change the growth, P/E or required return and see what you'd pay. Open the calculator →

Similar stocks · Biotechnology

About Seer, Inc.

Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software. This comprehensive solution empowers researchers to conduct advanced proteomic studies across various applications, including therapeutic and diagnostic investigations, as well as clinical trials. The company markets its products exclusively for research applications, serving academic institutions, diverse life sciences and research laboratories, and biopharmaceutical and biotechnology enterprises. Notably, these offerings are intended for non-diagnostic and non-clinical purposes. Seer has established collaborative agreements with entities such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies. Originally incorporated in 2017 as Seer Biosciences, Inc., the company adopted its current name, Seer, Inc., in July 2018. Its headquarters are situated in Redwood City, California.

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of Nov 4, 2026. How the Payback Price works

SEER Stock: Superinvestors, Insider Trades & Valuation